ARTIMPLANT INTERIM REPORT JANUARY - MARCH 2011

ARTIMPLANT INTERIM REPORT JANUARY - MARCH 2011

• Net revenue amounted to SEK 5.4 million (4.8).*
 
• The net loss totaled SEK 3.9 million (4.7).
 
• Earnings per stock unit amounted to SEK -0.03 (-0.08).
 
• Artimplant's own sales as a proportion of total sales continued to
increase and were equivalent to 73% (51) of product sales.
 
• The launch of complementary Artelon® Tissue Reinforcement products has
commenced in the USA.
 
• A new product for the treatment of osteoarthritis in the thumb base
joint has been cleared for sale in Europe.
 
• A new CFO - Kjell Thörnbring has been recruited and he has taken up
his position.
N. B. This is a translation from Swedish. The Swedish version shall
always take precedence.

Artimplant will not hold a telephone conference by reason of this
report. For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year
 

For additional information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com (hans.rosen@artimplant.com)
Kjell Thörnbring, CFO, phone +46 (0)31-746 56 54, +46 (0)703 11 90 25,
kjell.thornbring @artimplant.com (lars-johan.cederbrant@artimplant.com)

Further information at www.artimplant.com (http://www.artimplant.com/)
where one also can subscribe to future press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html (htt
p://www.artimplant.com/investors-media/subscribe-to-press-releases.html)

 

Artimplant
Artimplant's mission is to restore the health of patients by offering
medical professionals degradable implants that help the body to heal.

Artimplant is a medical technology company that restores health through
the development, production and marketing of degradable implants that
regenerate body functions and improve quality of life. Our products are
made from Artelon®, a biomaterial developed by the Company. Artimplant
produces implants for the treatment of osteoarthritis in hands and feet,
shoulder and other soft tissue injuries as well as oral and veterinary
applications. The Company's products are sold through licensees and own
sales under Artimplant's brand take place through agents and
distributors.

Artimplant is a public company listed on the NASDAQ OMX Stockholm in the
Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the
U.S. Private Securities Litigation Reform Act of 1995. Readers are
cautioned not to place undue reliance on these forward-looking
statements. Actual results may differ materially from those indicated by
these forward-looking statements as a result of risks and uncertainties
impacting the Company's business including increased competition; the
ability of the Company to expand its operations and to attract and
retain qualified professionals; technological obsolescence; general
economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the
Swedish Financial Instruments Act and the Swedish Securities Exchange
and Clearing Operations Act and/or stock market agreements. Information
was made available for publication on May 4 2011 at 11:30 AM (CET).